HEXO Corp. (TSX: HEXO; NASDAQ: HEXO) ("HEXO"), a leading producer
of high-quality cannabis products, today announced the execution of
a long-term supply agreement (the “Supply Agreement”) with
Entourage Health Corp. (TSX-V: ENTG) (OTCQX: ETRGF) (FSE: 4WE)
(“Entourage”), a Canadian producer and distributor of award-winning
cannabis products.
Under the Supply Agreement, HEXO will provide
Entourage with bulk dried cannabis and soft gel capsules, to be
marketed to patients and consumers under Entourage’s family of
brands. HEXO-branded products, including Gems cannabis soft gels,
Redebles gummies from Redecan, and selected Redees premium
pre-rolls as applicable, will also expand Entourage’s premium
product offerings available to respective patients of Starseed
Medicinal and Syndicate Cannabis medical marketplaces. This
strategic relationship will allow HEXO to better address the needs
of Canadian medical patients through Entourage’s medical channels.
At the same time, Entourage will benefit from HEXO's leading
cultivation and processing capabilities by obtaining a consistent
supply of quality-produced, top-shelf cannabis and soft gel
capsules to meet Entourage’s anticipated short-term demand.
“We are thrilled to partner with a like-minded
company that has an unparalleled understanding and dedication to
delivering the highest quality cannabis products to Canadians,”
said Charlie Bowman, CEO of HEXO Corp. “This relationship with
Entourage not only complements our growing health and wellness
portfolio, but also accelerates our ability to grow the business
and deliver premium cannabis products to more Canadians.”
“Collaborating with Entourage marks a
significant milestone for HEXO in the Canadian medical market and
highlights our commitment to addressing the range of consumer needs
and market demand. We see increasing opportunity in medicinal and
therapeutic products and believe the market fits well with our
high-quality products,” added Bowman.
"We are excited about the opportunities this new
relationship with HEXO brings to the medical cannabis market, which
provides greater access for our patients and consumers as we expand
our Starseed and Syndicate medical offerings, and distribution
commitments," said George Scorsis, CEO and Executive Chairman,
Entourage. "Leveraging HEXO’s cultivation capabilities will allow
us to more comprehensively service all our markets and provide
patients and consumers with a premium, consistent supply of
cannabis. Securing a long-term wholesale supply commitment from
HEXO also ensures that Entourage is well positioned to meet the
growing demand for all its branded products, while we continue
optimizing our operations.”
Supply Agreement Terms
The Supply Agreement provides for minimum annual
purchase commitments by Entourage, with year-over-year increases.
The prices of all products supplied under the Supply Agreement are
fixed but subject to limited and periodical adjustments depending
on prevailing production costs and market pricing. It includes
exclusivity for HEXO in supplying the specified products, subject
to certain exceptions including Entourage’s right to supply itself
with such products. The Supply Agreement has a three-year term,
which can be renewed for an additional three years at Entourage’s
election on the same terms and conditions, subject to increased
minimum annual purchase commitments over the course of the renewed
term.
A copy of the Supply Agreement will be made
available on Entourage’s profile on SEDAR at www.sedar.com.
Forward-Looking Statements
This press release contains forward-looking
information and forward-looking statements within the meaning of
applicable securities laws ("Forward-Looking Statements").
Forward-Looking Statements are based on certain expectations and
assumptions and are subject to known and unknown risks and
uncertainties and other factors that could cause actual events,
results, performance and achievements to differ materially from
those anticipated in these Forward-Looking Statements.
Forward-Looking Statements should not be read as guarantees of
future performance or results. Readers are cautioned not to place
undue reliance on these Forward-Looking Statements, which speak
only as of the date of this press release. HEXO and Entourage
disclaim any intention or obligation, except to the extent required
by law, to update or revise any Forward-Looking Statements as a
result of new information or future events, or for any other
reason.
This press release should be read in conjunction
with HEXO’s management’s discussion and analysis and consolidated
financial statements and notes thereto as at and for the year ended
July 31, 2022. Additional information about HEXO is available on
HEXO’s profile on SEDAR at www.sedar.com and EDGAR
at www.sec.gov, including HEXO’s Annual
Information Form for the year ended July 31, 2022 dated October 31,
2022.
Any forward-looking information speaks only as
of the date on which it is made, and, except as required by law,
Entourage does not undertake any obligation to update or revise any
forward-looking information, whether as a result of new
information, future events or otherwise. New factors emerge from
time to time, and it is not possible for Entourage to predict all
such factors. When considering this forward-looking information,
readers should keep in mind the risk factors and other cautionary
statements in Entourage’s disclosure documents filed with the
applicable Canadian securities regulatory authorities on SEDAR at
www.sedar.com. The risk factors and other factors noted in the
disclosure documents could cause actual events or results to differ
materially from those described in any forward-looking
information.
About HEXO Corp.HEXO is an
award-winning licensed producer of innovative products for the
global cannabis market. HEXO serves the Canadian recreational
market with a brand portfolio including HEXO, Redecan, UP Cannabis,
Original Stash, 48North, Trail Mix, Bake Sale and Latitude brands,
and the medical market in Canada and Israel. HEXO also serves the
Colorado market through its Powered by HEXO® strategy and Truss CBD
USA, a joint venture with Molson-Coors. With the completion of
HEXO's acquisitions of Redecan and 48North, HEXO is a leading
cannabis products company in Canada by recreational market share.
For more information, please visit hexocorp.com.
About Entourage Health
Corp.Entourage Health Corp. is the publicly traded parent
company of Entourage Brands Corp. (formerly WeedMD RX Inc.) and
CannTx Life Sciences Inc., licence holders producing and
distributing cannabis products for both the medical and adult-use
markets. Entourage owns and operates a state-of-the-art hybrid
greenhouse and processing facility located on 158-acres in
Strathroy, ON; a fully licensed 26,000 sq. ft. Aylmer, ON
processing facility, specializing in cannabis extraction; and a
micropropagation, tissue culture and genetics centre-of-excellence
in Guelph, Ontario. With its Starseed Medicinal medical-centric
brand and marketplace, Entourage has an industry-first, exclusive
partnership with LiUNA, the largest construction union in Canada,
who together with employers and other union groups, facilitate
access for insured medical patients. With the launch of Syndicate,
Entourage now hosts another unique medical marketplace that offers
patients a collective of Canadian micro-cultivators’ products,
along with Entourage’s family of brands. Entourage’s elite
adult-use product portfolio includes Color Cannabis, Saturday
Cannabis and Royal City Cannabis Co.– sold across eight provincial
distribution agencies. It is the exclusive Canadian producer and
distributor of award-winning U.S.-based wellness brand Mary’s
Medicinals sold in both medical and adult-use channels. Under a
collaboration with The Boston Beer Company subsidiary, Entourage is
also the exclusive distributor of cannabis-infused beverages
‘TeaPot’ in Canada, which launched in select provinces summer
2022.
For HEXO media or investor inquiries
please contact:Hayley Suchanek, Kaiser & Partners
hayley.suchanek@kaiserpartners.com
For Entourage media or investor
inquiries please contact:Marianella
delaBarrera416-897-6644marianella@entouragecorp.com
HEXO (TSX:HEXO)
過去 株価チャート
から 10 2024 まで 11 2024
HEXO (TSX:HEXO)
過去 株価チャート
から 11 2023 まで 11 2024